Company intelligence / Profile preview

Meltsnow

Brentwood, Tennessee, United Statesmeltsnow.com ↗

Ownership: Private
Development stage: Other

Overview

Melt Pharmaceuticals has reported positive Phase 3 topline efficacy results for its lead product candidate MELT-300, an opioid-free, sublingual tablet designed to provide needle-free procedural sedation. The company aims to address unmet needs in short-duration procedures such as cataract surgery by offering a non-IV and non-opioid alternative. Pivotal Phase 3 data were reported in November 2024 with further development ongoing toward commercialization.

Therapeutic areas: OphthalmologyOther
Modalities: Small moleculeSublingual tablet formulation (for sedation/analgesia)
Industry: Biotech

Beyond the preview

Go deeper on Meltsnow.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Meltsnow.

Explore the full profile